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Hepatitis C virus (HCV) infects human hepatocytes through several host factors. However, other pre-
requisite factors for viral entry remain to be identiﬁed. Using a yeast two-hybrid screen, we found
that human phospholipid scramblase 1 interacts with HCV envelope proteins E1 and E2. These phys-
ical interactions were conﬁrmed by co-immunoprecipitation and GST pull-down assays. Knocking
down the expression of PLSCR1 inhibited the entry of HCV pseudoparticles. Moreover, PLSCR1 was
required for the initial attachment of HCV onto hepatoma cells, where it speciﬁcally interacted with
entry factor OCLN. We show that PLSCR1 is a novel attachment factor for HCV entry.
Structured summary of protein interactions:
OCLN physically interacts with PLSCR1 by anti tag coimmunoprecipitation (View interaction)
E2 physically interacts with PLSCR1 by anti tag coimmunoprecipitation (View interaction)
PLSCR1 physically interacts with E2 by anti tag coimmunoprecipitation (View interaction)
PLSCR1 physically interacts with OCLN by anti tag coimmunoprecipitation (View interaction)
PLSCR1 physically interacts with E2 by pull down (View interaction)
E1 physically interacts with PLSCR1 by two hybrid (View interaction)
E2 physically interacts with PLSCR1 by two hybrid (View interaction)
PLSCR1 physically interacts with E1 by anti tag coimmunoprecipitation (View interaction)
E2 physically interacts with PLSCR1 by pull down (View interaction)
E1 physically interacts with PLSCR1 by pull down (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Previous studies identiﬁed a number of entry factors, includingHepatitis C virus (HCV) causes acute and chronic hepatitis,
which is often associated with an increased risk of developing
chronic liver disease and hepatocellular carcinoma [1]. The eluci-
dation of HCV entry factors and entry mechanisms will help the
development of small animal models and antiviral therapeutics;
however, the knowledge of HCV entry into host remains limited.
HCV glycoproteins E1 and E2 assemble as a non-covalent com-
plex, which is presented on the surface of HCV particles. E1 and E2
are the major viral proteins that bind to host entry factors [2].chemical Societies. Published by E
ratory of Proteomics, Beijing
ion Medicine, 33 Life Science
67872436 (W. Yang), +86 10
Yang), hefc@nic.bmi.ac.cnCD81 [3], scavenger receptor class B type I (SR-BI) [4], claudin-1
(CLDN1) [5], occludin (OCLN) [6,7], L-SIGN [8] and DC-SIGN [9].
CD81 acts at a stage after virus binding [3]. The identiﬁcation of
SR-BI as a HCV entry factor was reported with HCV pseudoparticles
(HCVpp) and conﬁrmed with HCV cell culture (HCVcc) [10]. CLDN1
spans the plasma membrane four times and is a component of the
tight junction (TJ) barrier that restricts the free exchange of ions
and aqueous molecules between cells [11]. During HCV entry,
CLDN1 plays a role at the post-binding stage and is required for
HCV envelope glycoprotein-mediated fusion [5]. Recently, OCLN
was identiﬁed as an HCV entry factor [6]. It has been showed that
the down-regulation of CLDN1 and OCLN results in a reduction of
HCV glycoprotein-dependent cell-to-cell fusion, which implicates
their role in the fusion process [7]. DC-SIGN and L-SIGN could func-
tion as capture factors for HCV and transmit infectious virions to
neighboring hepatocytes [12]. Additionally, the tight junction pro-
teins CLDN6 and CLDN9 were reported to have a role during HCVlsevier B.V. All rights reserved.
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host factors.
To explore novel interactions between host proteins and the
HCV envelope proteins E1 and E2, a yeast two-hybrid screen
was performed. PLSCR1, a calcium-dependent plasma membrane
protein, was identiﬁed to interact with both E1 and E2. PLSCR1
participates in the transbilayer movement of phospholipids
across the plasma membrane [14]. The transbilayer movement
usually happens after cellular injury or apoptosis [15]. PLSCR1
is a receptor for the secretory leukocyte protease inhibitor and
interacts with CD4 at the plasma membrane [16]. Particularly,
PLSCR1 binds to EGF and involves in EGF-induced clathrin-coated
endocytosis [17]. As we know, HCV entry depends on clathrin-
mediated endocytosis [18]. We speculate that PLSCR1 involves
in HCV entry. Our results demonstrate that PLSCR1 interacts with
HCV envelope proteins and participates in cellular entry during
HCV infection.
2. Materials and methods
2.1. Co-immunoprecipitation assay
HEK293T cells were transfected with Flag-PLSCR1 and CMV-
E1E2, Flag-E2 and Myc-PLSCR1, Flag or Myc empty vector as
control. Cells were harvested 48 h later and lysed in HEPES lysis
buffer [0.2% NP-40, 150 mM NaCl, 1% (v/v) Tween 20, 50 mM
Tris–HCl (pH 7.5), 10% glycerol, 0.1% 1 M DTT and protease inhib-
itor cocktail]. Immunoprecipitations were performed using anti-
Flag or anti-Myc antibodies and protein A/G-agarose at 4 C.
Beads were washed with HEPES lysis buffer and proteins were
eluted. Lysates and immunoprecipitates were detected using the
indicated primary antibodies, followed by detection with ECL
substrate.
2.2. GST pull-down assay
The soluble E2 (sE2) construct was a gift from Dr. Tianyi Wang
(The University of Pittsburg, USA). The recombinant protein was
secreted by HEK293T cells. Other GST-fused proteins (GST-E1,
GST-E2 and GST-PLSCR1) were expressed in Escherichia coli BL21
by induction with IPTG. The cells were harvested and sonicated
in pre-TGEM buffer (1% NP-40, 3% 5 M NaCl, 0.1% 1 M DTT and pro-
tease inhibitor cocktail). The GST-fused proteins were puriﬁed with
glutathione-sepharose 4B (Amersham Pharmacia Biotech, Piscata-
way, NJ) beads. Beads were washed with pre-TGEM buffer and pro-
teins were eluted. Divided aliquots were incubated with cellular
extracts (Myc-PLSCR1, Flag-PLSCR1 or sE2). Bound proteins were
analyzed by Western blotting.
2.3. Pseudovirus production
HCV pseudoparticle (HCVpp) packaging was performed as de-
scribed [19]. The plasmids OH8was from Dr. Linqi Zhang (Tsinghua
University, China). The envelope-deﬁcient pseudotype (Env-pp)
and VSV-G pseudotype were generated as controls.
For lentivirus-mediated gene overexpression and RNAi, on the
day before transfection, HEK293T cells (5  105) were seeded in
6 well plate. The next day a total of 3.0 lg DNA was transfected
using 6 ll Lipofectamine 2000 (Invitrogen). The following plasmid
mixtures and ratios (by weight) were transfected: (a) MLV gag-pol,
(b) VSV-G and (c) the desired transgene or shRNA. The ratio of
MLV Gag-Pol, VSV-G, and the desired transgene or shRNA is
5:1:5. Media was replaced after 4–6 h, supernatants containing
the pseudoparticles were harvested at 48 h and 72 h after
transfection.2.4. RNA interference
To knock down the expression of PLSCR1 in Huh7.5.1 cells, a
pQSuper-R lentiviral shRNA system was employed. The target se-
quences of shRNA were as follows: PLSCR1 (50-GATCCC
CAGTCTCCTCAGGAAATCTGTTCAAGAGACAGATTTCCTGAGGAGACT
TTTTTC-30), and non-speciﬁc (50-GATCCCCGGACGTCCTGGATTTA
GTGTTCAAGAGACACTAAATCCAGGACGTCCTTTTTC-30). Stable cell
lines were selected with puromycin. The positive clone with the
lowest level PLSCR1 was used in the following experiments.
2.5. HCVcc production and infection assay
The production of cell culture-generated HCV (HCVcc, JFH-1
strain, a generous gift from Dr. Wakita, The University of Tokyo, Ja-
pan) was performed as described [20]. For infection, HCVcc
(MOI = 1.0) was inoculated into the cells, and the infected cells
were grown for 72 h before qRT-PCR analysis.
2.6. HCVcc attachment assay
Stable knock-down Huh7.5.1 cells were grown on 24-well
plates (2  104). On the next day, the target cells were washed with
cold culture medium once, then were incubated with HCVcc
(MOI = 0.1) and HEPES (20 mM) at 4 C. As a positive control, hep-
arin (The ﬁnal concentration is 250 lg/ml) was added. Cells were
washed three times with cold PBS and prepared for qRT-PCR.
2.7. In-cell Western assay
Stable knock-down cell lines of Huh-7.5.1 were inoculated into
96-well plates. On the next day, target cells were infected with
HCVcc. After 72 h of infection, cells were washed and ﬁxed with
3% formaldehyde at room temperature. Then, cells were washed
three times with PBS containing 0.1% Triton X-100, and the pri-
mary antibody for HCV core protein was added and incubated
overnight at 4 C. The plates were washed. The red ﬂuorescent la-
beled secondary antibody was added to each well and incubated
for 60 minutes with gentle shaking. The plates were washed with
PBS and scanned immediately using the Odyssey Infrared Imaging
System. The virus foci formation data was quantiﬁed according to
the Odyssey Infrared Imaging System handbook.
2.8. Real-time PCR
Total RNAs were extracted from HCV-infected cells, and real-
time PCR was performed with the QuantiFastTM SYBR Green RT-
PCR kit (Qiagen, Foster city, CA). The level of HCV genomic RNA
was quantiﬁed using a qRT-PCR method (with primers 50-
GTCTAGCCATGGCGTTAGTA-30 and 50-CTCCCGGGGCACTCGCAAGC-
30). The fold changes were shown in three independent experi-
ments, each performed in triplicate.
2.9. Supplementary materials and methods
The other materials and methods were provided in Supplemen-
tary data.
3. Results
3.1. PLSCR1 physically interacts with HCV E1 and E2
To identify novel HCV E1 and E2 interacting proteins, we
screened a human liver cDNA library using the yeast two-hybrid
technology. PLSCR1 was found to associate with both E1 and E2
Fig. 1. Validation of E1-PLSCR1 and E2-PLSCR1 interactions. (A) and (B). Conﬁrmation of E1-PLSCR1 and E2-PLSCR1 interaction by GST pull-down. GST-E1 or GST-E2 puriﬁed
on glutathione beads was used as an afﬁnity matrix to pull down Myc tagged PLSCR1. (C) GST-PLSCR1 puriﬁed on glutathione beads was used as an afﬁnity matrix for pull
down sE2. After being washed, proteins bound to agarose beads were boiled in sample buffer, fractionated on a SDS–PAGE gel and analyzed by Western blot analysis. (D) and
(E) Validation of E1-PLSCR1 and E2-PLSCR1 interactions by co-immunoprecipitation. Both E1 and E2 proteins are expressed in D. Extracts and immunoprecipitates from
HEK293T cells were detected with indicated antibodies. The experiments were repeated at least three times.
Fig. 2. HCVpp entry is inhibited by stable knock-down of PLSCR1 expression in
Huh-7.5.1 cells. Huh-7.5.1 cells stably expressing a control shRNA or PLSCR1-
speciﬁc shRNA constructs were infected with Env-pp, HCVpp (OH8) and VSVpp for
1.5 h and then incubated at 37 C for 1.5 h. The supernatants were removed and
cells were added to 1 ml of fresh medium and incubated at 37 C for 48 h. Cells were
lysed for a luciferase assay according to the manufacturer’s instructions. The
expression of PLSCR1 was silenced in Huh-7.5.1 cells were subjected to immuno-
blotting using rabbit anti-PLSCR1 and anti-beta-actin monoclonal antibodies and
HRP-conjugated secondary antibodies. All The experiments were independently
repeated three times. For each graph data are means + S.E.M. (n = 3), P < 0.05.
Fig. 3. Knock-down of PLSCR1 inhibits HCV initial attachment to target cells. Huh-
7.5.1 cells stably expressing a control shRNA or PLSCR1-speciﬁc shRNA constructs.
Total RNA was analyzed by qRT-PCR to determine HCV RNA levels. All The
experiments were independently repeated three times. For each graph data are
means + S.E.M. (n = 3), P < 0.05.
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Myc-tagged PLSCR1 was expressed in HEK293T cells, and the
lysates were incubated with agarose beads immobilized by
GST-E1 and GST-E2 (Fig. 1A and B). Soluble HCV E2 (sE2) is the
2650 Q. Gong et al. / FEBS Letters 585 (2011) 2647–2652soluble ectodomain of envelope glycoprotein E2. Thus, we tested
the interaction by pull-down assay and demonstrated an associa-
tion between GST-PLSCR1 and sE2 (Fig. 1C). Results showed that
GST-E1 and GST-E2, but not GST alone, bound to PLSCR1, GST-
PLSCR1 associate with sE2. Furthermore, co-immunoprecipitation
results showed that PLSCR1 speciﬁcally immunoprecipitated with
E1 by anti-Flag antibody (Fig. 1D), but no E1 was detected in con-
trol lanes. The association of E2 and PLSCR1 proteins was con-
ﬁrmed by immunoprecipitation with anti-Myc antibody. E2 only
co-precipitated with PLSCR1 when co-expressed in HEK293T cells
(Fig. 1E). These results indicate that PLSCR1 physically interacts
with HCV E1 and E2 in vitro. Furthermore, we suggest that the do-
mains between 99 and 290 aa in PLSCR1 mediates the association
with E2 by co-immunoprecipitation assays (Supplementary Fig. 2).
3.2. HCVpp entry is inhibited by stable knock-down of PLSCR1
expression in Huh-7.5.1 cells
Due to the plasmamembrane localization of PLSCR1 [16] and its
ability to interact with HCV glycoproteins, the virus entry might be
regulated by PLSCR1. Particles pseudotyped with HCV envelope
proteins were generated. The Env-pp and VSVpp were used as con-
trols. Target cells were seeded onto 24-well plates, the supernatant
containing Env-pp, HCVpp or VSVpp was added into each well and
transfected by a centrifuge method (2500 rpm, 90 min, 30 C).
Then, the cells were incubated at 37 C for 1.5 h. The supernatants
were removed and the cells were incubated at 37 C for 48 h. Cells
were lysed for a luciferase assay. As shown in Fig. 2, compared with
control cells, HCVpp entry was signiﬁcantly inhibited in PLSCR1
knock-down cells. Meanwhile, a similar inhibition was also ob-
served with VSVpp, but an enhancement with the inﬂuenza virusFig. 4. Silencing of PLSCR1 in Huh-7.5.1 cells results in inhibition of HCV particles produ
(empty) and transfected cells were subjected to immunoblotting using rabbit anti-PLSCR
7.5.1 were then infected with HCVcc. For infection, HCVcc (MOI = 1.0) was inoculated for
and incubated at 37 C for 72 h. Cells were analyzed by (A) real-time PCR or by (B) In-
quantiﬁed. No HCVcc means non-infected cells as a control. All the above experimentspseudoparticles (Supplementary Fig. 3). The cell viability was mea-
sured using a CCK8 (Cell Counting Kit-8) assay, which showed that
knock-down of PLSCR1 does not inﬂuence the cell viability (Sup-
plementary Fig. 4). The suppression of endogenous PLSCR1 after
stable shRNA was conﬁrmed by Western blot (Fig. 2, lower panel).
3.3. Knock-down of PLSCR1 inhibits HCV initial attachment to target
cells
To explore whether PLSCR1 involves in the HCV initial attach-
ment, we carried out HCVcc attachment assay. Huh-7.5.1 cells sta-
bly expressing a non-target control shRNA or PLSCR1-speciﬁc
shRNA constructs were washed with ice-cold culture medium once
and then infected with HCVcc or HCVcc + heparin for 1 h at 4 C
(Heparin is a homolog of highly sulfated heparan sulfate and used
as a control to reduce HCV attachment to the cell surface). Un-
bound viral particles were removed, and total RNA was analyzed
by qRT-PCR to determine HCV RNA levels. As shown in Fig. 3,
knock-down of PLSCR1 inhibits HCV initial attachment to target
cells.
3.4. Suppression of PLSCR1 expression inhibits HCVcc infection
To further conﬁrm the role of PLSCR1 during HCV infection, a
JFH-1 derived HCVcc was employed. First, we established
Huh7.5.1 cells that were stably transfected with either a PLSCR1
shRNA cassette targeting PLSCR1 30-UTR or an empty vector as a
control. The cells were inoculated with HCVcc and quantiﬁed for
HCV RNA by qRT-PCR or virus foci formation by in cell Western.
As shown in Fig. 4A and B, the knock-down of PLSCR1 signiﬁcantly
abated the quantity of infectious HCV particles (more than 80% inction. Huh-7.5.1 cells were transfected with shRNA as described. Lysates of control
1 and anti-beta-actin monoclonal antibodies. Stable knock-down cell lines of Huh-
3 h, the supernatants were removed and cells were added to 1 ml of fresh medium
cell Western. The virus foci formation data of the In-cell Western experiment was
were independently repeated three times.
Fig. 5. PLSCR1 interacts with OCLN. HEK293T cells were transfected with indicated plasmids and detected by Western blot using indicated antibodies. (A) and (B) OCLN was
immunoprecipitated with PLSCR1 by reciprocal co-immunoprecipitation assays. The experiments were independently repeated three times.
Q. Gong et al. / FEBS Letters 585 (2011) 2647–2652 2651Fig. 4A and 25% in Fig. 4B). These results suggest that PLSCR1 par-
ticipates in HCV infection in vitro.
3.5. PLSCR1 co-precipitates with OCLN
The aforementioned results suggest that PLSCR1 might interact
with other entry factors to coordinately regulate the HCV infec-
tion. To explore this possibility, we tested the protein interaction
of PLSCR1 and known HCV entry factors by co-immunoprecipita-
tion assays. Notably, PLSCR1 co-precipitated with OCLN (Fig. 5A
and Fig. 5B). However, PLSCR1 was unable to interact with CD81,
CLDN1 and SR-BI in a co-immunoprecipitation assay (Supplemen-
tary Fig. 5).
4. Discussion
We identiﬁed for the ﬁrst time that PLSCR1 contributes to HCV
entry and infection through HCVpp and HCVcc assays. Moreover,
PLSCR1 plays an important role in the initial attachment of HCV
with target cells. These ﬁndings imply that PLSCR1 plays a crucial
role in HCV entry into hepatocytes.
HCV is an enveloped virus, which enters into host cells through
a few entry factors. The virus entry is initiated by the binding of the
viral particle to attachment factors, followed by cellular clathrin-
mediated endocytosis through which viruses are internalized by
endosomes [21]. The HCV particle is composed of a nucleocapsid,
which surrounded by a lipid bilayer. The two envelope glycopro-
teins, E1 and E2, form non-covalent heterodimers and plays an
important role in HCV entry [22]. A few proteins have been identi-
ﬁed as putative entry factors for HCV entry, such as CD81 [3,23],
SR-BI [4], CLDN1 [5], and OCLN [6]. We identiﬁed PLSCR1 as a
new protein that interacting with both E1 and E2. PLSCR1 regulates
signaling transduction through several receptors, including the
epidermal growth factor receptor (EGFR) [24,25] and the high-
afﬁnity IgE receptor [26,27]. EGF initiates rapid internalization of
both the PLSCR1 and EGFR receptors via clathrin-coated pits [17].
PLSCR1 involves in EGF-induced clathrin-mediated endocytosis.
The down-regulation of factors involved in clathrin-mediated
endocytosis inhibits HCVpp and HCVcc infection [28]. But whether
PLSCR1 is involved in HCV infection and the detailed mechanisms
remains unknown. Our results showed that the stable knock-down
of PLSCR1 inhibits HCVpp and HCVcc infection in Huh-7.5.1 cells.
Moreover, we showed that the stable knock-down of PLSCR1 also
abate the entry of VSVpp (Fig. 2). It might due to that VSV entry
also depend on clathrin-mediated endocytosis [29]. Furthermore,
PLSCR1 is involved in the initial attachment of HCV virus to target
cells. All of the results imply that PLSCR1 affects clathrin-mediated
endocytosis and involves in HCV entry.
To conﬁrm the essential region of PLSCR1 that participated in
the interaction with E2, a set of PLSCR1 mutants was constructed.
We showed that the palmitoylation mutation of PLSCR1 (5C? 5A)
or the double mutant of palmitoylation motif and NLS sequence of
PLSCR1 (5C? 5A, K? A) did not affect the binding with E2. Fromthe results of deletion mutants, the region between 99 and 290 aa
of PLSCR1 is crucial to the interaction of E2 and PLSCR1, which con-
tains SH2, SH3 and Ca2+ binding domains (Supplementary Fig. 2).
The HCVpp model is a valuable tool to investigate host cell en-
try factors that involves in virus entry. We found that PLSCR1 phys-
ically interacts with E1 and E2 and mediates the entry process of
HCVpp infection (Fig. 2). HCVcc is the more authentic tool to study
HCV entry and infection. So we used HCVcc assay to determine
whether PLSCR1 contribute HCV entry or/and infection, results
showed that knock-down of PLSCR1 inhibit HCVcc attachment
and infection to Huh-7.5.1 cells (Fig. 3). We also conﬁrmed that
PLSCR1 interacts with OCLN. Further investigate the mechanisms
of PLSCR1 in the HCV infection will facilitate the development of
new approaches for the treatment of HCV infection and HCV in-
duced liver disease.
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